2014
DOI: 10.2147/ceor.s39212
|View full text |Cite
|
Sign up to set email alerts
|

A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases

Abstract: The treatment of inflammatory bowel disease with standard therapy fails to control the disease in many patients. Biologic therapy has an increasing role in altering the natural history of Crohn’s disease and ulcerative colitis, and is improving patient prognosis. However, indications for treatment and issues with drug costs and value for money remain unclear. Also, when to perform early intervention with biologic agents is at present unclear. We performed an extensive literature search and review to address th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0
1

Year Published

2015
2015
2023
2023

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 73 publications
0
6
0
1
Order By: Relevance
“…The economic burden of IBD is changing whereby costs are increasingly driven by biologic agents and less by hospitalisations and surgery [ 13 ]. Despite the high costs of biologic agents, increasing use of these agents is seen due to their efficacy [ 14 ].…”
Section: Introductionmentioning
confidence: 99%
“…The economic burden of IBD is changing whereby costs are increasingly driven by biologic agents and less by hospitalisations and surgery [ 13 ]. Despite the high costs of biologic agents, increasing use of these agents is seen due to their efficacy [ 14 ].…”
Section: Introductionmentioning
confidence: 99%
“…26 Several drugs including steroids and biologics are used for the treatment of UC; the drawbacks to these therapies are the exorbitant cost and their serious side effects. 27,28 Most research into the prevention of UC has been directed toward the use of nontoxic plant phytocompounds that modulate colonic immunity and redox signaling via antioxidative and anti-inflammatory mechanisms. [29][30][31] We have previously demonstrated the pharmacological effect of 6G in acute colitis through short-term administration of DSS to mice.…”
Section: Discussionmentioning
confidence: 99%
“…), while up to two-thirds of the costs were so-called indirect costs due to sick-leave, disablement pension and early retirements [36,[44][45][46] . The introduction of new expensive treatment modalities, mainly biological therapies, has increased the direct costs in IBD management [47] . Biological treatment might have the potential to reduce the frequency of disease worsening and complications, improve health-related quality of life and maintain work capacity among IBD patients [48,49] .…”
Section: Economymentioning
confidence: 99%